Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

73 HCV patient study and the potential to see viral load reduction with a favorable tolerability profile at the higher dose; and (vi) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


    Condensed Consolidated Financial Statements

                 
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... when a patient has sepsis, a life-threatening condition in ... -- often too fast for antibiotics to help. A ... by a team at Harvard,s Wyss Institute for Biologically ... sepsis. , "Even with the best current treatments, ... least 30 percent of the time," said Mike Super, ...
(Date:9/15/2014)... Bioptigen announced today the availability of ... optical device metrology and pre-clinical ophthalmic research markets. ... Contact Lens Metrology is designed for non-destructive, non-contact, full ... IOL structures, and donor tissues. The metrology ... in a hydration bath (saline), automated segmentation of anterior ...
(Date:9/15/2014)... 15, 2014 Research and Markets has ... by Product, by Services, by Technology, by Application - Global ... Whole Exome Sequencing (WES) is next-generation technology used for ... exon. The exome, which is the total of all exons ... and is actually converted into proteins after translation. It is ...
(Date:9/15/2014)... ANNAPOLIS, Maryland , 15. September 2014 /PRNewswire/ ... Week (IPAW) wird vom 12. bis 18. ... der Plasma Protein Therapeutics Association (PPTA) ... Ziele: , Das globale Bewusstsein für ... Den Beitrag von Plasmaspendern beim Retten und Verbessern ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3
... 10 Senesco Technologies , Inc. ("Senesco" or ... on July 9, 2009, the Company entered into a definitive purchase ... (i) up to 1,111,111 shares of its common stock (the "Shares") ... an aggregate of up to 1,000,000 shares of common stock, which ...
... July 10 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... the research, development, manufacture, marketing and,distribution of probiotics dietary ... 10:00 a.m. EDT on Wednesday, July 15, 2009, to ... full year ended March,31, 2009. , ...
... of Energy,s Lawrence Berkeley National Laboratory and the University ... fabricate efficient solar cells from low-cost and flexible materials. ... of nanoscale pillars, each a single crystal, with dimensions ... take advantage of abundant solar energy we have to ...
Cached Biology Technology:Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 2Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 3Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 4China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results 2Nanopillars promise cheap, efficient, flexible solar cells 2Nanopillars promise cheap, efficient, flexible solar cells 3
(Date:9/16/2014)... extravagant, colorful tail feathers in courtship of a peahen. ... camera developed by an engineer at Washington University in ... choose their mates based on a similar display. , ... used a bioinspired polarization camera developed by Viktor Gruev, ... Washington University, to make the discovery. His camera has ...
(Date:9/16/2014)... the Exxon Valdez spilled 11 million gallons of oil ... up another giant oil spill in the Gulf of ... the Journal of Consumer Research , news coverage ... instead of catalyzing changes in the way fossil fuels ... media coverage of these two events helped to resolve ...
(Date:9/16/2014)... season of bounty. Fungi of dizzying variety erupt from ... search of elusive but delectable wild mushrooms. Part of ... hunt, and their mysterious not-quite-meat, not-quite-vegetable qualities that belie ... you are eating known to science? , The Fungi ... some estimates range up to 10 million species, only ...
Breaking Biology News(10 mins):Camera developed at WUSTL sheds light on mate choice of swordtail fish 2Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3
... study, a University of Oklahoma researcher and collaborators found a ... toxicity of water or sediment was resistant to insecticides used ... first to demonstrate that the indicator species may adapt to ... source of information about ecosystem health. ...
... are believed to contribute to the debilitating progression of ... in important brain functions, like cell-to-cell communication and immunological ... protein levels in the brain, binding to messenger RNAs ... Dr. Boaz Barak and a team of researchers in ...
... rodents known as Murinae (mice, rats, etc.), which first ... the entire Old World (Eurasia, Africa, Australia) in less ... have long suspected that one of the reasons for ... apparatus. Now, researchers have used the brilliant X-ray beams ...
Cached Biology News:OU research team finds a common bioindicator resistant to insecticides 2Untangling Alzheimer's disease 2Untangling Alzheimer's disease 3Chewing their way to success 2
... 100 Instrument System is ideal for ... Upstate's Beadlyte reagents. The Luminex 100 ... with software version 1.7, the XY ... Upstate offers $2000 in free Beadlyte ...
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
A431 cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: